Randomized Trialhigh evidence
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.
The New England journal of medicine·September 11, 2025·PMID 40888697
Why it mattersBeta-blockers are standard first-line therapy for obstructive HCM despite limited evidence. This trial provides head-to-head data showing a cardiac myosin inhibitor as monotherapy may offer superior functional and hemodynamic benefits.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled